Breast carcinoma with amplified HER2: a gene expression signature specific for trastuzumab resistance and poor prognosis
暂无分享,去创建一个
C. Morrison | Song Liu | R. Cheney | N. Nowak | J. Conroy | T. Khoury | Dan Wang | F. Ademuyiwa | W. Mojica | K. Kanehira
[1] Pan Du,et al. lumi: a pipeline for processing Illumina microarray , 2008, Bioinform..
[2] M. Pegram. Can we circumvent resistance to ErbB2-targeted agents by targeting novel pathways? , 2008, Clinical breast cancer.
[3] G. Mills,et al. Preclinical Testing of Clinically Applicable Strategies for Overcoming Trastuzumab Resistance Caused by PTEN Deficiency , 2007, Clinical Cancer Research.
[4] S. Hunt,et al. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] C. Hudis. Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.
[6] N. Brünner,et al. Concentrations of TIMP1 mRNA splice variants and TIMP-1 protein are differentially associated with prognosis in primary breast cancer. , 2007, Clinical chemistry.
[7] E. Winer,et al. Predictors of Resistance to Preoperative Trastuzumab and Vinorelbine for HER2-Positive Early Breast Cancer , 2007, Clinical Cancer Research.
[8] Thomas J. Smith,et al. Do the large benefits justify the large costs of adjuvant breast cancer trastuzumab? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Jorma Isola,et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. , 2006, The New England journal of medicine.
[10] R. Nahta,et al. Herceptin: mechanisms of action and resistance. , 2006, Cancer letters.
[11] D. Hicklin,et al. Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts , 2006, Clinical Cancer Research.
[12] Ryuji Kobayashi,et al. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. , 2005, Cancer research.
[13] Greg Yothers,et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Dowsett,et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.
[15] Greg Yothers,et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.
[16] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[17] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[18] S. Batra,et al. Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy , 2004, British Journal of Cancer.
[19] Jean YH Yang,et al. Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.
[20] Naoto T. Ueno,et al. P27kip1 Down-Regulation Is Associated with Trastuzumab Resistance in Breast Cancer Cells , 2004, Cancer Research.
[21] D. Slamon,et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. , 2004, Journal of the National Cancer Institute.
[22] L. Goldstein,et al. HER-2 testing in breast cancer using parallel tissue-based methods. , 2004, JAMA.
[23] Ming Tan,et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. , 2004, Cancer cell.
[24] M. Owens,et al. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. , 2004, Clinical breast cancer.
[25] Gordon K Smyth,et al. Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .
[26] C. A. Carraway,et al. Muc4/Sialomucin Complex in the Mammary Gland and Breast Cancer , 2001, Journal of Mammary Gland Biology and Neoplasia.
[27] M. Piccart-Gebhart,et al. Node positive breast cancer , 2003 .
[28] M. Pollak,et al. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. , 2002, Medical science monitor : international medical journal of experimental and clinical research.
[29] Yudong D. He,et al. A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .
[30] Chi-Hung Lin,et al. Resistance to tamoxifen‐induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer , 2002, International journal of cancer.
[31] Y. Lu,et al. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). , 2001, Journal of the National Cancer Institute.
[32] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[33] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[34] Louis M Weiner,et al. New approaches to antibody therapy , 2000, Oncogene.
[35] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[36] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[37] Y. Yarden,et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. , 1996, The EMBO journal.
[38] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[39] E. Robecchi. [Pathology of the breast]. , 1954, Minerva ginecologica.